MNPR

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Monopar Therapeutics Inc

NASDAQ | MNPR

98.50

USD

$0.00

(

0.00%

)

At Close (As of Oct 14, 2025)

$629.65M

Market Cap

-

P/E Ratio

-3.84

EPS

$105.00

52 Week High

$4.50

52 Week Low

HEALTHCARE

Sector

MNPR Chart

Recent Chart
Price Action

MNPR Technicals

Tags:

MNPR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$16M
Selling General And Administrative $3.2B
Research And Development $13M
Operating Expenses $16M
Investment Income Net -
Net Interest Income $404K
Interest Income $404K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $16M
Income Before Tax -$16M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$16M
Comprehensive Income Net Of Tax -
Ebit -$32M
Ebitda -$16M
Net Income -$16M

Revenue & Profitability

Earnings Performance

MNPR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $60M
Total Current Assets $60M
Cash And Cash Equivalents At Carrying Value $46M
Cash And Short Term Investments $46M
Inventory -
Current Net Receivables -
Total Non Current Assets $60B
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $14M
Other Current Assets $79K
Other Non Current Assets -
Total Liabilities $5.3M
Total Current Liabilities $5.3M
Current Accounts Payable $2.3M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $3M
Other Non Current Liabilities -
Total Shareholder Equity $55M
Treasury Stock -
Retained Earnings -$76B
Common Stock $6.1K
Common Stock Shares Outstanding $3.8M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$6.4M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$14M
Cashflow From Financing $59M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$16M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$16M
Selling General And Administrative $3.2B
Research And Development $13M
Operating Expenses $16M
Investment Income Net -
Net Interest Income $404K
Interest Income $404K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $16M
Income Before Tax -$16M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$16M
Comprehensive Income Net Of Tax -
Ebit -$32M
Ebitda -$16M
Net Income -$16M

MNPR News

MNPR Profile

Monopar Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Wilmette, Illinois, focused on the development of proprietary therapies aimed at enhancing clinical outcomes for cancer patients. With a robust pipeline of innovative drug candidates, Monopar is committed to addressing unmet medical needs in oncology. Its strategic approach encompasses leveraging advanced drug formulation technologies to optimize treatment efficacy and safety, positioning the company as a key player in the biopharmaceutical sector.

VHAI
+66.66%
$0.00
CGBS
-39.47%
$0.03
BITF
+28.33%
$5.39
UGRO
+71.96%
$0.63
YYAI
-22.88%
$0.13
BURU
-21.69%
$0.40
INTC
+2.33%
$37.22
QBTS
+23.01%
$40.61
SSKN
+48.00%
$2.27
ITP
+19.97%
$0.31
NVTS
+20.93%
$12.05
AXDX
-61.36%
$0.03
NVDA
-3.28%
$182.13
LAES
+11.41%
$6.83
CAN
+13.81%
$1.73
CRML
+15.76%
$26.94
EDHL
+79.75%
$0.89
BYND
-22.73%
$0.79
MP
+21.34%
$95.06
PLUG
+0.38%
$3.91
IONQ
+16.19%
$82.09
MNTS
+30.76%
$1.87
KDLY
-1.56%
$0.85
RGTI
-4.27%
$52.55
NAK
+3.94%
$2.76
RMBL
+60.50%
$3.21
JDZG
+32.97%
$2.50
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AMZN
+1.71%
$220.07
IONZ
+10.03%
$2.53
SRM
+53.27%
$10.30
UUUU
+3.70%
$24.65
AMD
+1.83%
$220.40
DNN
-0.81%
$3.05
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
TSLA
-2.60%
$424.55
DVLT
+7.57%
$1.82
WLGS
-5.57%
$0.04
AREC
+34.05%
$6.67
ETHD
+11.40%
$3.70
TMQ
+10.62%
$6.56
GPUS
-9.48%
$0.38
UAMY
-0.26%
$16.66
ETWO
0.00%
$3.30
VZ
-0.25%
$39.75
NUAI
+35.36%
$3.18
USAR
-3.83%
$37.19
WULF
+8.50%
$15.19
TLRY
-3.84%
$1.62
AFMD
-34.94%
$0.18
CIFR
+0.19%
$20.38
ERIC
+17.07%
$9.56
ADAP
-15.26%
$0.15
WWR
+13.27%
$2.89
IREN
+0.82%
$64.67
PLTR
+1.70%
$180.23
APLD
+5.70%
$36.19
OPI
-16.97%
$0.20
GWH
-9.09%
$8.22
ABAT
+5.90%
$9.76
KLG
-9.05%
$13.35
NIO
-4.28%
$6.87
CORZ
+3.72%
$19.21
GRYP
-10.38%
$1.38
GWAV
+89.77%
$16.14
SOFI
-0.46%
$27.01
SOUN
+3.78%
$19.86
ONDS
-6.61%
$10.09
MODV
-25.22%
$0.43
MARA
+3.65%
$20.98
ACHR
-5.12%
$12.11
BBD
+1.67%
$3.14
RGTZ
+5.16%
$9.77
ELAB
+83.43%
$9.55
FNB
+2.35%
$15.62
CLSK
+6.21%
$21.28
ATXS
+38.62%
$11.74
QS
-1.58%
$16.72
BMNR
-5.84%
$53.52
BMY
-0.95%
$43.54
NOK
+2.95%
$5.40
ASST
-5.54%
$1.02
F
+0.08%
$11.55
EXK
+10.96%
$8.50
BTBT
+0.75%
$4.03
VLY
+2.32%
$10.55
TBH
-48.33%
$1.24
DFLI
-1.68%
$1.54
NEHC
-9.61%
$2.35
SHOT
-74.37%
$0.39
EOSE
+2.05%
$17.39
RXRX
-3.79%
$5.32
GDXD
+1.06%
$0.74
NB
-3.88%
$10.88
ZAPP
-46.30%
$0.15
SLDP
+9.38%
$6.89
SNAP
-0.41%
$8.01
VHAI
+66.66%
$0.00
CGBS
-39.47%
$0.03
BITF
+28.33%
$5.39
UGRO
+71.96%
$0.63
YYAI
-22.88%
$0.13
BURU
-21.69%
$0.40
INTC
+2.33%
$37.22
QBTS
+23.01%
$40.61
SSKN
+48.00%
$2.27
ITP
+19.97%
$0.31
NVTS
+20.93%
$12.05
AXDX
-61.36%
$0.03
NVDA
-3.28%
$182.13
LAES
+11.41%
$6.83
CAN
+13.81%
$1.73
CRML
+15.76%
$26.94
EDHL
+79.75%
$0.89
BYND
-22.73%
$0.79
MP
+21.34%
$95.06
PLUG
+0.38%
$3.91
IONQ
+16.19%
$82.09
MNTS
+30.76%
$1.87
KDLY
-1.56%
$0.85
RGTI
-4.27%
$52.55
NAK
+3.94%
$2.76
RMBL
+60.50%
$3.21
JDZG
+32.97%
$2.50
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AMZN
+1.71%
$220.07
IONZ
+10.03%
$2.53
SRM
+53.27%
$10.30
UUUU
+3.70%
$24.65
AMD
+1.83%
$220.40
DNN
-0.81%
$3.05
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
TSLA
-2.60%
$424.55
DVLT
+7.57%
$1.82
WLGS
-5.57%
$0.04
AREC
+34.05%
$6.67
ETHD
+11.40%
$3.70
TMQ
+10.62%
$6.56
GPUS
-9.48%
$0.38
UAMY
-0.26%
$16.66
ETWO
0.00%
$3.30
VZ
-0.25%
$39.75
NUAI
+35.36%
$3.18
USAR
-3.83%
$37.19
WULF
+8.50%
$15.19
TLRY
-3.84%
$1.62
AFMD
-34.94%
$0.18
CIFR
+0.19%
$20.38
ERIC
+17.07%
$9.56
ADAP
-15.26%
$0.15
WWR
+13.27%
$2.89
IREN
+0.82%
$64.67
PLTR
+1.70%
$180.23
APLD
+5.70%
$36.19
OPI
-16.97%
$0.20
GWH
-9.09%
$8.22
ABAT
+5.90%
$9.76
KLG
-9.05%
$13.35
NIO
-4.28%
$6.87
CORZ
+3.72%
$19.21
GRYP
-10.38%
$1.38
GWAV
+89.77%
$16.14
SOFI
-0.46%
$27.01
SOUN
+3.78%
$19.86
ONDS
-6.61%
$10.09
MODV
-25.22%
$0.43
MARA
+3.65%
$20.98
ACHR
-5.12%
$12.11
BBD
+1.67%
$3.14
RGTZ
+5.16%
$9.77
ELAB
+83.43%
$9.55
FNB
+2.35%
$15.62
CLSK
+6.21%
$21.28
ATXS
+38.62%
$11.74
QS
-1.58%
$16.72
BMNR
-5.84%
$53.52
BMY
-0.95%
$43.54
NOK
+2.95%
$5.40
ASST
-5.54%
$1.02
F
+0.08%
$11.55
EXK
+10.96%
$8.50
BTBT
+0.75%
$4.03
VLY
+2.32%
$10.55
TBH
-48.33%
$1.24
DFLI
-1.68%
$1.54
NEHC
-9.61%
$2.35
SHOT
-74.37%
$0.39
EOSE
+2.05%
$17.39
RXRX
-3.79%
$5.32
GDXD
+1.06%
$0.74
NB
-3.88%
$10.88
ZAPP
-46.30%
$0.15
SLDP
+9.38%
$6.89
SNAP
-0.41%
$8.01
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.